Page results
-
UCLH provides an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
We provide an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
UCLH is a centre of excellence in the management of patients with acute and chronic leukaemia. We provide an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
UCLH is a centre of excellence in the management of patients with acute and chronic leukaemia.
-
Mindfulness patient information.
-
The bone marrow transplant and haematopoietic stem cell transplant service at UCLH is the largest in Europe and provides a full range of transplant services.
-
This page is for patients having planned neurosurgery.
-
UCLH is a designated Haemophilia Centre providing a 24/7 service for patients, including those needing treatment with blood products and clotting factor medications.
-
Thalassaemia is a group of inherited blood conditions where the part of the blood known as haemoglobin is abnormal.
-
The COVID Medicines Delivery Unit (CMDU gives new COVID-19 treatments for patients at highest risk in the community from the NCL sector. These treatments involve intravenous infustion of neutralising monoclonal antibodies (nMABs) or oral antiviral treatments, which are given to high-risk patients who have had a positive PCR test.
File results
-
FOI/2024/0401 - Hospital treatments for abortion complications
-
FOI/2024/0402 - Various IT systems used at the Trust
-
FOI/2024/0403 - Risk Policy and corporate risk register
-
FOI/2024/0406 - Staff and patient discrimination complaints in 2021, 2022 and 2023
-
FOI/2024/0409 - Number of A&E attendees with mental health complaints from 2022 to 2024
-
FOI/2024/0412 - Healthcare travel costs scheme for patients
-
FOI/2024/0415 - Biologic and targeted medications within dermatology medicine
-
FOI/2024/0416 - Home dialysis treatment
-
FOI/2024/0417 - Funding for point-of-care home blood monitoring devices for cancer patients
-
FOI/2024/0420 - Commercialisation of NHS patient data